Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Approved Drugs for Genetic Disease in Clinical Development in CANADA

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Apotex Inc.

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              2ND EUROPEAN HEALTHTECH CEO FORUM

              Participation Not Confirmed

              Update your events

              Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)

              Contact the Supplier

              Lead Product(s): Deferiprone

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: CHIESI USA INC

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition January 13, 2020

              Details:

              Chiesi Group expands distribution network via acquisition for worldwide product rights.

              PharmaCompass__DigitalAd